Disease of the Month – Hemolytic uremic syndrome

Shots:

Hemolytic uremic syndrome (HUS) is a serious, potentially life-threatening condition in which damage to the small blood vessels in the kidneys interferes with their ability to function properly

With the Disease of Month report, we break down complex medical topics into clear, meaningful insights for global readers. By highlighting conditions that impact communities worldwide, we aim to keep our readers informed, engaged, and empowered

This edition delivers a comprehensive yet easy-to-read overview of HUS, covering its key characteristics, types, symptoms, and diagnostic approaches. It also explores current treatment options, epidemiology, market landscape, ongoing clinical trials, active patient advocacy groups (PAGs), and inspiring patient stories, offering a well-rounded perspective on both the science and the human impact of the disease

For a detailed analysis and customized insights on HUS, contact our team at connect@pharmashots.com

Hemolytic uremic syndrome (HUS) is a rare but serious condition in which damage to tiny blood vessels triggers a cascade of complications, including low platelet counts, destruction of red blood cells, and sudden kidney dysfunction. While most cases are associated with Shiga toxin–producing infections, others stem from dysregulation of the body’s complement system or are linked to underlying illnesses, genetic variations, or certain medications.

Often perceived solely as a kidney disorder, HUS can in fact affect multiple organ systems, with neurological symptoms occurring in a significant number of patients. The wide variation in its causes and clinical presentation makes early recognition critical. When diagnosed promptly and managed appropriately, patient outcomes can improve markedly, underscoring the importance of awareness, timely intervention, and informed care. [1]

HUS does not follow a single, predictable pattern. Instead, it presents in multiple forms, each reflecting distinct underlying disease mechanisms. Historically, the presence of bloody diarrhea was used to differentiate typical, Shiga toxin–associated HUS from other variants. Today, however, it is well recognized that atypical HUS can also present with this symptom, blurring traditional clinical boundaries.

As these features increasingly overlap, clinicians now favor an etiology-based classification that focuses on the root cause of the disease. This approach enables more accurate diagnosis and supports better-informed clinical decision-making. Broadly, HUS is categorized into several types, including:

Typical HUS: Most HUS cases, nearly 90% are caused by E. coli strains that produce Shiga toxins. Infection usually occurs through contaminated food or water, or through close contact with an infected individual. While exposure does not always lead to illness, approximately 5–15% of those infected develop HUS, with young children being particularly vulnerable.

Atypical HUS: Atypical HUS (aHUS) accounts for about 5–10% of cases and is most often driven by genetic abnormalities that disrupt regulation of the body’s complement system. The disease can be severe and progressive if left untreated, around half of affected patients may require dialysis, and mortality rates approach 25%. These outcomes underscore the critical importance of early diagnosis and timely, targeted care.

Secondary HUS: Secondary HUS arises as a complication of other conditions or infections, frequently involving immune system overactivation. One notable example is Streptococcus pneumoniae–associated HUS, which affects 5–15% of pediatric cases and requires prompt antibiotic treatment. Less common triggers include inherited vitamin B12 disorders, rare genetic mutations, and infections such as HIV. Across all forms, early recognition remains key to improving patient outcomes. [1]

In most cases, HUS is triggered by infection with specific strains of E. coli, particularly in children under five years of age. These high-risk strains produce Shiga toxin and are collectively known as Shiga toxin–producing E. coli (STEC).

While the majority of E. coli strains are harmless, a small subset can initiate the chain of events that leads to HUS. Beyond STEC, several other factors have been linked to the development of the condition, including:

Other infections: such as Streptococcus pneumoniae, HIV, or influenza

Certain medications: including select cancer therapies and immunosuppressive drugs used to prevent organ rejection

Complications of underlying conditions: in rare cases, pregnancy, autoimmune disorders, or malignancies

In addition, there is a rare inherited form known as atypical HUS (aHUS). Carrying a genetic predisposition does not necessarily result in disease; however, triggers such as infections, specific medications, or chronic health conditions can activate the condition, emphasizing the importance of vigilance and early intervention. [2]

HUS typically presents an abrupt onset, often beginning with gastrointestinal symptoms before progressing to signs of systemic and organ involvement. Early recognition of these warning signals is critical, as timely intervention can be pivotal in preventing acute kidney injury and other serious complications.

Gastrointestinal Onset

The initial phase of HUS is frequently characterized by gastrointestinal distress, including:

Diarrhea, often bloody and persistent

Cramping abdominal pain that may intensify rapidly

Nausea and vomiting, contributing to dehydration

Fever, chills, and general malaise, reflecting an underlying inflammatory or infectious process

As symptoms evolve, close monitoring is essential to identify progression beyond the gastrointestinal tract, particularly toward renal and hematologic involvement.

Early Systemic Signs

Persistent or worsening headaches, often intensifying as systemic involvement increases

Pallor of the skin or mucous membranes (inside the mouth or nose), indicating anemia from red blood cell destruction

Easy bruising or unusual bleeding, suggesting platelet consumption and impaired clotting

Neurological Symptoms

Confusion, difficulty concentrating, or altered mental status, signaling central nervous system involvement

Seizures, typically seen in more severe or advanced cases

Rare stroke-like symptoms, which may occur when cerebral blood flow is compromised

Cardiac and Circulatory Clues

Rapid or irregular heart rate (arrhythmias), reflecting cardiovascular stress

Progressive fatigue and weakness, driven by ongoing hemolysis and reduced oxygen delivery

Together, these symptoms highlight the multisystem nature of HUS and reinforce the importance of early diagnosis, close monitoring, and coordinated multidisciplinary management to mitigate life-threatening complications.

When Kidney Damage Begins

As HUS advances, the destruction of red blood cells and the formation of microthrombi can lead to widespread vascular injury. The kidneys—highly sensitive to disruptions in blood flow—are particularly vulnerable. As their ability to filter waste and maintain fluid balance declines, acute kidney injury (AKI) may rapidly develop, marking a critical turning point in disease progression.

Signs of Acute Kidney Injury

Early indicators of renal involvement may include:

Blood in the urine (hematuria), reflecting glomerular injury

Rising toxin levels, often presenting as a generalized feeling of illness or malaise

Elevated blood pressure, due to impaired fluid and electrolyte regulation

Shortness of breath (dyspnea), potentially resulting from fluid overload

Swelling of the legs, feet, or ankles (edema), signaling reduced renal clearance

Decreased urine output (oliguria), a key warning sign of worsening kidney function

Prompt identification of these symptoms is essential, as early intervention can help limit irreversible kidney damage and reduce the risk of long-term renal complications. [3]

Diagnosing HUS begins with a careful assessment by a healthcare provider, who will review the medical and family history and conduct a thorough physical examination. If HUS is suspected, the evaluation quickly advances to targeted laboratory and imaging tests, each providing crucial insights into the underlying disease process.

Key Tests Used to Diagnose HUS

1. Urinalysis (Pee Test)
A simple urine sample can reveal early signs of kidney stress:

Blood in the urine (hematuria)

Excess protein, signaling impaired renal function

2. Blood Tests
A blood sample can uncover multiple indicators of HUS progression:

Low red blood cell counts (anemia) from hemolysis

Low platelet levels, reflecting ongoing clotting activity

Organ function markers for kidneys and liver

3. Stool Tests
Testing a stool sample can identify infections that trigger HUS, such as:

E. coli O157

Other Shiga toxin–producing bacteria

4. Genetic Testing
Specialized labs may analyze a portion of your blood to detect:

Inherited genetic variants that increase HUS risk

Guidance on the most effective treatment strategy

5. Kidney Biopsy
A tiny sample of kidney tissue can provide a detailed look at:

The extent of renal damage

Clues to the underlying cause of injury

Putting the Puzzle Together

Each diagnostic tool reveals a different piece of the HUS puzzle:

Urinalysis uncovers early kidney involvement

Blood tests highlight anemia, thrombocytopenia, and organ function

Stool tests identify infectious triggers

Kidney biopsy confirms tissue-level damage and guides treatment

By combining these insights, healthcare providers can pinpoint the type, cause, and severity of HUS, enabling timely intervention and improving patient outcomes. [3]

Managing HUS requires prompt hospitalization and a coordinated approach to support kidney function, maintain fluid balance, and address the underlying disease mechanisms. Care focuses on stabilizing the patient, preventing complications, and enabling recovery.

1. IV Fluids and Nutritional Support

Intravenous (IV) fluids restore hydration and maintain electrolyte balance when the kidneys struggle to filter waste.

Tube feeding (enteral nutrition) may be provided if oral intake is insufficient, ensuring the body receives the energy and nutrients needed to support healing.

2. Medications

Blood pressure medications help manage hypertension, a common complication that can further strain the kidneys.

Targeted therapies for atypical HUS: Drugs like eculizumab or ravulizumab inhibit the overactive complement pathway responsible for the disease, directly addressing its root cause.

Vaccination is essential prior to treatment to protect against meningococcal and pneumococcal infections.

Antibiotics may be prescribed depending on infection risk or triggers, typically for at least two weeks.

3. Blood Transfusions

Red blood cell transfusions alleviate anemia-related symptoms, including fatigue, shortness of breath, and rapid heart rate.

Platelet transfusions support proper blood clotting, reducing the risk of excessive bruising or bleeding.

A Coordinated Approach

Effective HUS management combines supportive care, targeted therapy, and careful monitoring to protect kidney function, stabilize blood parameters, and reduce complications. Early intervention and personalized treatment strategies are key to improving outcomes for patients across all age groups. [3]

Surgery and Other Procedures: Advanced Interventions for HUS

For some patients with HUS, supportive care alone may not be enough. Depending on disease severity, complications, and underlying causes, your healthcare team may recommend specialized procedures to protect kidney function and stabilize overall health.

1. Kidney Dialysis

When the kidneys are unable to filter waste or remove excess fluids, dialysis temporarily takes over this critical function.

Many patients require dialysis only until kidney function recovers.

In cases of severe or lasting kidney damage, long-term dialysis may be necessary to maintain health and quality of life.

2. Plasma Exchange (Plasmapheresis)

Plasma, the liquid component of blood, circulates vital cells and proteins throughout the body. Plasmapheresis removes the patient’s plasma and replaces it with fresh or frozen donor plasma.

This process helps eliminate harmful substances from the bloodstream.

It is particularly beneficial for certain forms of HUS where immune-mediated damage drives the disease.

3. Kidney Transplant

For individuals with permanent or severe kidney damage, a kidney transplant may offer the most effective long-term solution.

Transplantation restores kidney function.

It can dramatically improve overall health and quality of life, offering patients renewed independence and hope. [2]

Global Incidence
HUS is a rare but serious condition with a measurable global footprint. Recent analyses estimate a crude global incidence of 0.66 cases per 100,000 person‑years, with a standardized incidence of 0.57 per 100,000.

While uncommon, these numbers underscore the importance of awareness, early detection, and access to specialized care, as even a single case can carry significant clinical consequences. [4]

Subtype-Specific Patterns

Typical HUS
Typical HUS accounts for the vast majority of cases, representing approximately 90–95% of all HUS diagnoses.

In children, particularly infants and toddlers, the most common form is STEC-HUS, triggered by Shiga toxin-producing E. coli infections. Early recognition in this population is critical, as timely intervention can significantly influence outcomes and prevent complications. [1]

Atypical HUS

Atypical HUS (aHUS) is far less common, representing a small fraction of all HUS cases. Prevalence varies by region and study, typically ranging from 2.2 to 9.4 cases per million in populations under 20 years of age. Across all age groups, one review estimates prevalence at approximately 4.9 per million.

The annual incidence of aHUS remains low, with reports ranging from 0.23 to 1.9 cases per million people per year, though regional differences exist. Despite its rarity, aHUS is a severe, life-altering condition, making early recognition and specialized care essential. [5]

Age Patterns

HUS and aHUS are most frequently observed in young children, particularly those under 5 years of age, with the highest incidence seen in patients younger than 10. Early childhood represents the period of greatest vulnerability, highlighting the importance of timely recognition and intervention to prevent serious complications. [1]

Race and Gender Patterns

HUS is relatively uncommon among Black individuals. Across populations, the condition appears to affect males and females at similar rates, highlighting that while race may influence prevalence, HUS shows no strong gender bias. [6]

The global HUS treatment market is entering a phase of sustained expansion, underscoring growing clinical recognition and evolving therapeutic demand. Valued at approximately USD 1.47 billion in 2024, the market is projected to nearly double, reaching USD 2.77 billion by 2033, supported by a strong CAGR of 7.2% over the forecast period.

This momentum is being fueled by rising patient awareness, continued advancements in laser-based and minimally invasive treatment technologies, and an increasing preference for effective, outcome-driven dermatologic and vascular care solutions. Together, these factors are reshaping treatment paradigms and elevating expectations for both efficacy and accessibility.

As demand for interventions addressing visible vascular and hematologic conditions continues to grow, the HUS market is well positioned for long-term growth, creating fertile ground for innovation, improved clinical outcomes, and expanded global access to next-generation therapies. [7]

ULTOMIRIS (ravulizumab-cwvz) represents a transformative advance in the treatment of aHUS, a rare and life-threatening disease driven by uncontrolled complement activation. Engineered to bind complement component C5 with high affinity, ULTOMIRIS inhibits its cleavage into C5a and C5b, effectively preventing formation of the membrane attack complex (MAC) and halting the cascade responsible for endothelial injury and thrombotic microangiopathy (TMA).

As a long-acting, targeted complement inhibitor, ULTOMIRIS delivers sustained control of disease activity with an extended dosing interval, addressing both the biological root of aHUS and the treatment burden faced by patients. Approved for use in adults and pediatric patients one month of age and older, it offers a unified therapeutic approach across age groups—bringing consistency, durability, and precision to aHUS management. [9]

By directly targeting the central driver of complement-mediated pathology, ULTOMIRIS is helping redefine long-term outcomes for patients with aHUS, marking a decisive shift toward durable disease control and a higher standard of care.

Eculizumab (SOLIRIS)

SOLIRIS marks a breakthrough in complement-targeted therapy. First approved by the FDA in 2007 and now established as a gold standard, this humanized monoclonal antibody is specifically indicated for diseases driven by uncontrolled complement activation for aHUS.

Ravulizumab-cwvz (ULTOMIRIS)

ULTOMIRIS marks a breakthrough in complement-mediated disease therapeutics. Approved by the FDA as a long-acting terminal complement inhibitor, this therapy is specifically indicated for adults and pediatric patients one month of age and older with HUS.

LNP023 (Fabhalta)

Iptacopan is a targeted inhibitor of Factor B in the alternative complement pathway. By modulating C3 cleavage, it reduces the generation of downstream effectors and limits amplification of the terminal complement pathway. Iptacopan is currently in P-III clinical development for the treatment of aHUS

RG6107

Crovalimab-akkz is a high-affinity mAb designed to selectively bind complement protein C5. By inhibiting C5 cleavage into C5a and C5b, crovalimab-akkz prevents formation of the membrane attack complex (MAC). The therapy is currently in P-III clinical development for the treatment of aHUS

The scientific effort to understand and treat HUS has entered a decisive new phase. What was once limited to scattered case reports and isolated interventions has matured into a coordinated, multi-phase global research ecosystem—one that is actively reshaping the therapeutic horizon.

Current Phase II and III trials are exploring a broad and sophisticated range of approaches. These include precision pharmacologic therapies, next-generation vasoconstrictors, targeted biologics, advanced device-based interventions, and pioneering gene and cell therapies aimed at addressing both retinal and cutaneous manifestations of the disease. Collectively, these programs are redefining how HUS may be diagnosed, managed, and ultimately treated in the years ahead.

Notably, much of this momentum is concentrated in the United States, where leading research institutions, specialized ophthalmology and dermatology networks, and a highly developed clinical trial infrastructure converge. This geographic focus is more than incidental, it serves as a powerful catalyst, accelerating patient recruitment, strengthening multi-center collaboration, and advancing the most promising candidates toward pivotal, practice-changing trials. [10]

Across the globe, dedicated patient organizations are playing a vital role in elevating patient voices, advancing research, and ensuring that individuals living with HUS receive the care and support they deserve. Beyond improving day-to-day quality of life, these groups are driving awareness, influencing health policy, supporting scientific innovation, and building strong communities. Through education, advocacy, and shared experience, they empower patients and families with knowledge, connection, and hope, helping transform the HUS journey at every stage.

Behind every diagnosis of HUS lies a human story, one of resilience, adaptation, and the quiet courage to keep moving forward. While the condition can range from a cosmetic concern to a marker of deeper systemic disease, the lived experiences of patients reveal far more than any clinical description can capture.

In this section, we spotlight remarkable individuals who have turned challenges into strength. Their stories illuminate the realities of navigating symptoms, seeking answers, finding the right care, and reclaiming confidence. These journeys not only inspire but also remind us why continued research, awareness, and compassionate support matter.

Julia

Julia’s symptoms began in April of 2012 when she was 14 years old and about to finish eighth grade. At school one day, she became tired and nauseous and had trouble focusing. Over the next few days, she developed a piercing pain in her abdomen. Eventually, the pain was so intense that her parents brought her to the emergency room.

She was admitted and treated for a suspected bacterial infection with antibiotics and pain medicine and discharged once her symptoms subsided.

Over the next year and a half, Julia was admitted to the hospital several more times. She saw countless physicians and underwent many tests and medical procedures, including a bone marrow biopsy, renal biopsy, and multiple platelet and blood infusions. “I saw doctors in oncology, rheumatology, nephrology, infectious disease, hematology—all different specialties. It was hard to see that many specialties and hear them all say, ‘I don’t know,’” recalls Julia.

The summer before her sophomore year of high school, Julia’s condition deteriorated. Besides unbearable pain and nausea, she was experiencing kidney failure. Her father rushed her to a specialist at a hospital more than 100 miles away, hoping they would finally find the root of her symptoms. “I was watching Julia in my passenger seat, all curled up in excruciating pain, trying to console her the best I could. I wish no parent would have to see their child go through that,” remembers Julia’s father, David.

Julia was ultimately diagnosed with aHUS, a rare, genetic, chronic, and life-threatening disease that can either be caused by genetics or a trigger that can progressively damage vital organs that can lead to stroke, heart attack, kidney failure, and death. Once confirming this diagnosis, Julia’s doctors were able to begin to manage her aHUS.

“I remember the day I was diagnosed. It was relieving because not only was there a diagnosis but there was an answer. That was the most relieving part about it,” recalls Julia.

Erica

Erica was expecting to have a fun family vacation at the beach, but instead spent a week exhausted in bed with a fever, sore throat, and chills. Unfortunately, her condition did not improve, and Erica went to the emergency room after she became very dizzy. That visit turned into 27 days of in-patient care at the hospital.

After months of being misdiagnosed and with little improvement in her symptoms, Erica’s doctors determined that she was suffering from aHUS, a rare, life-threatening, chronic genetic disease that can either be caused by genetics or a trigger that can progressively damage vital organs that can lead to stroke, heart attack, kidney failure, and death.

Over the next year, Erica underwent dialysis and experienced nausea, exhaustion, and blood clots. Her kidneys became severely damaged, and she lost vision in her left eye due to a retinal blood clot. She tried to keep up with her work and daily activities, but her illness became too much. She took a leave of absence from her job as a preschool teacher and applied to receive a kidney transplant.

Eventually, Erica and her physician were able to get her aHUS under control. Her kidney function improved, and she no longer required a transplant. She went back to work full-time and resumed her daily activities, something she once thought would never be possible.

“When my aHUS kept me from going to work and doing what I love, I began to lose hope. I’m so thankful that I am back to living my life.”

Advances in haematological care are paving the way for managing conditions like HUS and helping patients like Julia and Erica the symptoms with confidence

References: